Trial Profile
A Randomized, Double Blind Multicenter Study to Evaluate the Long-term Safety and Efficacy of VI-0521 Relative to Placebo in Providing and Maintaining Glycemic Control in Type 2 Diabetic Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2021
Price :
$35
*
At a glance
- Drugs Phentermine/topiramate (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors VIVUS
- 24 Feb 2015 Results were presented, as per Vivus Inc. media release.
- 06 Oct 2014 Results published online in Diabetes Care, according to a VIVUS media release.
- 10 Apr 2013 New trial record